Literature DB >> 31047915

Escherichia coli vectors having stringently repressible replication origins allow a streamlining of Crispr/Cas9 gene editing.

Swaminath Srinivas1, Zhe Hu2, John E Cronan3.   

Abstract

Readily curable plasmids facilitate the construction of plasmid-free bacterial strains after the plasmid encoded genes are no longer needed. The most popular of these plasmids features a temperature-sensitive (Ts) pSC101 origin of replication which can readily revert during usage and cannot be used to construct Ts mutations in essential genes. Plasmid pAM34 which contains an IPTG-dependent origin of replication largely overcomes this issue but is limited by carrying the most commonly utilized antibiotic selection and replication origin. This study describes the construction of an expanded series of plasmid vectors having replication origins of p15a, RSF1030 or RSF1031 that like pAM34 have IPTG-dependent replication. Surprisingly, these plasmids can be cured in fewer generations than pAM34. Derivatives of pAM34 with alternative antibiotic selection markers were also constructed. The utility of these vectors is demonstrated in the construction of a CRISPR-Cas9 system consisting of an IPTG-dependent Cas9 plasmid and a curable guide RNA plasmid having a streptomycin counterselection marker. This system was successfully demonstrated by construction of point mutations, deletions and insertions in the E. coli genome with a very high efficiency and in a shorter timescale than extant methods. The plasmids themselves were readily cured either together or singly from the resultant strains with minimal effort.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31047915      PMCID: PMC7260698          DOI: 10.1016/j.plasmid.2019.04.004

Source DB:  PubMed          Journal:  Plasmid        ISSN: 0147-619X            Impact factor:   3.466


  29 in total

1.  High copy number plasmids compatible with commonly used cloning vectors.

Authors:  G J Phillips; S K Park; D Huber
Journal:  Biotechniques       Date:  2000-03       Impact factor: 1.993

2.  An Eight-Residue Deletion in Escherichia coli FabG Causes Temperature-Sensitive Growth and Lipid Synthesis Plus Resistance to the Calmodulin Inhibitor Trifluoperazine.

Authors:  Swaminath Srinivas; John E Cronan
Journal:  J Bacteriol       Date:  2017-04-25       Impact factor: 3.490

Review 3.  Plasmid transformation of Escherichia coli and other bacteria.

Authors:  D Hanahan; J Jessee; F R Bloom
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

4.  One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products.

Authors:  K A Datsenko; B L Wanner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  Scarless Cas9 Assisted Recombineering (no-SCAR) in Escherichia coli, an Easy-to-Use System for Genome Editing.

Authors:  Christopher R Reisch; Kristala L J Prather
Journal:  Curr Protoc Mol Biol       Date:  2017-01-05

Review 6.  The Biology of CRISPR-Cas: Backward and Forward.

Authors:  Frank Hille; Hagen Richter; Shi Pey Wong; Majda Bratovič; Sarah Ressel; Emmanuelle Charpentier
Journal:  Cell       Date:  2018-03-08       Impact factor: 41.582

7.  Analysis of gene control signals by DNA fusion and cloning in Escherichia coli.

Authors:  M J Casadaban; S N Cohen
Journal:  J Mol Biol       Date:  1980-04       Impact factor: 5.469

8.  High-efficiency counterselection recombineering for site-directed mutagenesis in bacterial artificial chromosomes.

Authors:  Alexander W Bird; Axel Erler; Jun Fu; Jean-Karim Hériché; Marcello Maresca; Youming Zhang; Anthony A Hyman; A Francis Stewart
Journal:  Nat Methods       Date:  2011-12-04       Impact factor: 28.547

9.  Design, construction and characterization of a set of insulated bacterial promoters.

Authors:  Joseph H Davis; Adam J Rubin; Robert T Sauer
Journal:  Nucleic Acids Res       Date:  2010-09-15       Impact factor: 16.971

Review 10.  CRISPR-Cas guides the future of genetic engineering.

Authors:  Gavin J Knott; Jennifer A Doudna
Journal:  Science       Date:  2018-08-31       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.